Literature DB >> 3282748

Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.

M LeBel1, M Spino.   

Abstract

The issue of whether it is better to administer antibiotics as an intermittent bolus dose or a continuous intravenous infusion has been debated for several decades. This paper reviews the extensive literature on the topic, considering both the pharmacokinetic and pharmacodynamic aspects of antibacterials as well as experimental results from studies conducted in vitro, in animals and in humans. It is evident from reviewing the literature that neither mode of administration is clearly superior to the other. The decision regarding the mode of administration must take into account the antibiotic being used, the bacteria, the patient and the infection, as well as the pharmacokinetics of the particular drug in the individual patient. The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) are useful indicators of the relative in vitro effectiveness of antibiotics, but it is not clear what relevance these parameters have to the desired antibiotic concentrations in vivo. Furthermore, questions of serum vs tissue fluid concentrations, peak concentrations vs AUC, and free vs total concentration are all important issues to consider in assessing the optimal mode of administration. The importance of newer indices such as the post-antibiotic effect are now beginning to be recognised. A number of scientists are actively engaged in developing a system to identify the most appropriate mode of administration based upon the integration of an antibiotic's pharmacodynamics and pharmacokinetics. Within the next few years we anticipate that appropriate guidelines should have been developed to aid the optimisation of parenteral administration, at least for some antibiotics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282748     DOI: 10.2165/00003088-198814020-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  60 in total

1.  Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness.

Authors:  W H Hall; D N Gerding; E A Schierl
Journal:  J Infect Dis       Date:  1977-06       Impact factor: 5.226

2.  Serum bactericidal rate as measure of antibiotic interactions.

Authors:  L L Briceland; M T Pasko; J M Mylotte
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 3.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

4.  Influence of the route of administration on the pharmacokinetics of amikacin.

Authors:  J M Lanao; A Dominguez-Gil; J M Tabernero; L Corbacho
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Effects of method of antibiotic administration on extravascular penetration: cross-over study of cefazolin given by intermittent injection or constant infusion.

Authors:  L R Peterson; D N Gerding; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1981-01       Impact factor: 5.790

6.  Gentamicin intravenous infusion rate: effect on interstitial fluid concentration.

Authors:  A J Kozak; D N Gerding; L R Peterson; W H Hall
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

7.  Effect of method of administration on extravascular penetration of four antibiotics.

Authors:  L L Van Etta; G R Kravitz; T E Russ; C E Fasching; D N Gerding; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

8.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

9.  The etiology and persistence of cryptic bacterial infections: a hypothesis.

Authors:  J W Costerton
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

10.  Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia.

Authors:  M Pechère; R Letarte; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1987-04       Impact factor: 5.790

View more
  10 in total

Review 1.  The treatment of staphylococcal infections with special reference to pharmacokinetic, pharmacodynamic and pharmacoeconomic considerations.

Authors:  R Janknegt
Journal:  Pharm World Sci       Date:  1997-06

2.  Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.

Authors:  J E Connors; J T DiPiro; R G Hayter; K D Hooker; J A Stanfield; T R Young
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Authors:  Y J Valcke; M T Rosseel; R A Pauwels; M G Bogaert; M E Van der Straeten
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

Authors:  P J Wood; L L Ioannides-Demos; E B Bastone; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.

Authors:  E B Bastone; S C Li; L L Ioannides-Demos; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation.

Authors:  G Potel; J Caillon; B Fantin; J Raza; F Le Gallou; J Y Lepage; P Le Conte; D Bugnon; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

7.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 8.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 9.  Time course of trough serum gentamicin concentrations in preterm and term neonates.

Authors:  M A de Cos; J Gómez-Ullate; F Gómez; J A Armijo
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

10.  Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.

Authors:  G Potel; J Caillon; F Le Gallou; D Bugnon; P Le Conte; J Raza; J Y Lepage; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.